These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 29689561)

  • 1. Urate-Lowering Agents in Asymptomatic Hyperuricemia: Role of Urine Sediment Analysis and Musculoskeletal Ultrasound.
    Viggiano D; Gigliotti G; Vallone G; Giammarino A; Nigro M; Capasso G
    Kidney Blood Press Res; 2018; 43(2):606-615. PubMed ID: 29689561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A two-stage approach to the treatment of hyperuricemia in gout: the "dirty dish" hypothesis.
    Perez-Ruiz F; Herrero-Beites AM; Carmona L
    Arthritis Rheum; 2011 Dec; 63(12):4002-6. PubMed ID: 21898351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urate-lowering agents for asymptomatic hyperuricemia in stage 3 - 4 chronic kidney disease: Controversial role of kidney function.
    Jeon HJ; Oh J; Shin DH
    PLoS One; 2019; 14(6):e0218510. PubMed ID: 31206563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of asymptomatic hyperuricemia and prevention of vascular disease: a decision analytic approach.
    Akkineni R; Tapp S; Tosteson AN; Lee A; Miller KL; Choi HK; Zhu Y; Albert DA
    J Rheumatol; 2014 Apr; 41(4):739-48. PubMed ID: 24584921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Gout and Hyperuricemia in CKD.
    Vargas-Santos AB; Neogi T
    Am J Kidney Dis; 2017 Sep; 70(3):422-439. PubMed ID: 28456346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultrasonography in the diagnosis of asymptomatic hyperuricemia and gout.
    Puig JG; Beltrán LM; Mejía-Chew C; Tevar D; Torres RJ
    Nucleosides Nucleotides Nucleic Acids; 2016 Dec; 35(10-12):517-523. PubMed ID: 27906639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comorbidity in gout and hyperuricemia: prevalence, causes, prospects of urate lowering therapy].
    Eliseev MS; Novikova AM
    Ter Arkh; 2019 May; 91(5):120-128. PubMed ID: 32598686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
    Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. To Treat or Not to Treat? Effect of Urate-Lowering Therapy on Renal Function, Blood Pressure and Safety in Patients with Asymptomatic Hyperuricemia: A Systematic Review and Network Meta-Analysis.
    Tien YY; Shih MC; Tien CP; Huang HK; Tu YK
    J Am Board Fam Med; 2022; 35(1):140-151. PubMed ID: 35039419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uric acid-lowering effect of dotinurad, a novel selective urate reabsorption inhibitor, in hypertensive patients with gout or asymptomatic hyperuricemia: a pooled analysis of individual participant data in phase II and III trials.
    Takahashi T; Beppu T; Hidaka Y; Hosoya T
    Clin Exp Hypertens; 2021 Nov; 43(8):730-741. PubMed ID: 34425059
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
    Wortmann RL; Macdonald PA; Hunt B; Jackson RL
    Clin Ther; 2010 Dec; 32(14):2386-97. PubMed ID: 21353107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan.
    Yu KH; Chen DY; Chen JH; Chen SY; Chen SM; Cheng TT; Hsieh SC; Hsieh TY; Hsu PF; Kuo CF; Kuo MC; Lam HC; Lee IT; Liang TH; Lin HY; Lin SC; Tsai WP; Tsay GJ; Wei JC; Yang CH; Tsai WC
    Int J Rheum Dis; 2018 Apr; 21(4):772-787. PubMed ID: 29363262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia.
    Levy GD; Rashid N; Niu F; Cheetham TC
    J Rheumatol; 2014 May; 41(5):955-62. PubMed ID: 24692523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing hyperuricemia and gout in chronic kidney disease: a clinical conundrum.
    Premachandra KH; Day RO; Roberts DM
    Curr Opin Nephrol Hypertens; 2021 Mar; 30(2):245-251. PubMed ID: 33399392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of urate-lowering therapy in hyperuricemia on slowing the progression of renal function: a meta-analysis.
    Wang H; Wei Y; Kong X; Xu D
    J Ren Nutr; 2013 Sep; 23(5):389-96. PubMed ID: 23131573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia].
    Fujimori S
    Nihon Rinsho; 2008 Apr; 66(4):729-35. PubMed ID: 18409523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study.
    Kataoka H; Mochizuki T; Ohara M; Tsuruta Y; Iwasa N; Yoshida R; Tsuchiya K; Nitta K; Kimura K; Hosoya T;
    Sci Rep; 2022 Mar; 12(1):3784. PubMed ID: 35260678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD.
    Sato Y; Feig DI; Stack AG; Kang DH; Lanaspa MA; Ejaz AA; Sánchez-Lozada LG; Kuwabara M; Borghi C; Johnson RJ
    Nat Rev Nephrol; 2019 Dec; 15(12):767-775. PubMed ID: 31296965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hyperuricemia and gout: diagnosis and therapy].
    Tausche AK; Unger S; Richter K; Wunderlich C; Grässler J; Roch B; Schröder HE
    Internist (Berl); 2006 May; 47(5):509-20; quiz 521. PubMed ID: 16586130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.